107 related articles for article (PubMed ID: 28522586)
1. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
Virani NA; Thavathiru E; McKernan P; Moore K; Benbrook DM; Harrison RG
Cancer Lett; 2018 Jul; 425():174-182. PubMed ID: 29574275
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
4. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature.
Van Rite BD; Krais JJ; Cherry M; Sikavitsas VI; Kurkjian C; Harrison RG
Cancer Invest; 2013 Oct; 31(8):505-10. PubMed ID: 24083814
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
7. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Guillen KP; Restuccia A; Kurkjian C; Harrison RG
Pancreas; 2015 Aug; 44(6):945-52. PubMed ID: 25899647
[TBL] [Abstract][Full Text] [Related]
8. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
9. Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.
Guillen KP; Ruben EA; Virani N; Harrison RG
Protein Eng Des Sel; 2017 Feb; 30(2):85-94. PubMed ID: 27986920
[TBL] [Abstract][Full Text] [Related]
10. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.
Cejka D; Preusser M; Woehrer A; Sieghart W; Strommer S; Werzowa J; Fuereder T; Wacheck V
Cancer Biol Ther; 2008 Sep; 7(9):1377-85. PubMed ID: 18708754
[TBL] [Abstract][Full Text] [Related]
11. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
12. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.
Juan TY; Roffler SR; Hou HS; Huang SM; Chen KC; Leu YL; Prijovich ZM; Yu CP; Wu CC; Sun GH; Cha TL
Clin Cancer Res; 2009 Jul; 15(14):4600-11. PubMed ID: 19584154
[TBL] [Abstract][Full Text] [Related]
14. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
Zeng Q; Yang Z; Gao YJ; Yuan H; Cui K; Shi Y; Wang H; Huang X; Wong ST; Wang Y; Kesari S; Ji RR; Xu X
Eur J Cancer; 2010 Apr; 46(6):1132-43. PubMed ID: 20156674
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
16. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
[TBL] [Abstract][Full Text] [Related]
17. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract][Full Text] [Related]
18. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate.
Miki K; Xu M; Gupta A; Ba Y; Tan Y; Al-Refaie W; Bouvet M; Makuuchi M; Moossa AR; Hoffman RM
Cancer Res; 2001 Sep; 61(18):6805-10. PubMed ID: 11559554
[TBL] [Abstract][Full Text] [Related]
19. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
20. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]